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H-Ferritin-nanocaged olaparib: a 
promising choice for both BRCA-
mutated and sporadic triple 
negative breast cancer
S. Mazzucchelli  1, M. Truffi1, F. Baccarini1, M. Beretta1, L. Sorrentino1, M. Bellini2, M. A. 
Rizzuto2, R. Ottria1, A. Ravelli3, P. Ciuffreda  1, D. Prosperi2 & F. Corsi1,4
Poly(ADP-ribose) polymerase (PARP) inhibitors represent a promising strategy toward the treatment 
of triple-negative breast cancer (TNBC), which is often associated to genomic instability and/or BRCA 
mutations. However, clinical outcome is controversial and no benefits have been demonstrated in wild 
type BRCA cancers, possibly due to poor drug bioavailability and low nuclear delivery. In the attempt 
to overcome these limitations, we have developed H-Ferritin nanoformulated olaparib (HOla) and 
assessed its anticancer efficacy on both BRCA-mutated and non-mutated TNBC cells. We exploited 
the natural tumor targeting of H-Ferritin, which is mediated by the transferrin receptor-1 (TfR1), and 
its physiological tropism toward cell nucleus. TNBC cell lines over-expressing TfR-1 were successfully 
recognized by H-Ferritin, displaying a fast internalization into the cells. HOla induced remarkable 
cytotoxic effect in cancer cells, exhibiting 1000-fold higher anticancer activity compared to free olaparib 
(Ola). Accordingly, HOla treatment enhanced PARP-1 cleavage, DNA double strand breaks and Ola 
delivery into the nuclear compartment. Our findings suggest that H-Ferritin nanoformulation strongly 
enhances cytotoxic efficacy of Ola as a stand-alone therapy in both BRCA-mutated and wild type TNBC 
cells, by promoting targeted nuclear delivery.
In the era of tailored medicine, breast cancer (BC) is often successfully treated by targeted therapy1. Hormonal 
and anti-HER2 therapies are the treatment of choice for luminal BC and HER2-positive BC, respectively1. 
However, targeted therapy is not available for triple-negative breast cancer (TNBC), a BC subtype associated to 
poor clinical outcome and frequent local and distant recurrence. Therefore, combinatorial cytotoxic chemother-
apy remains the recommended option for TNBC treatment2–4. In recent years, the interest of clinicians has moved 
toward poly(ADP-ribose) polymerase (PARP) inhibitors, which act by causing impairment of one of the main 
mechanisms of DNA repair, i.e. the base excision repair (BER)5. PARP inhibitors offer a promising therapeutic 
strategy for cancers that are deficient in Breast Related Cancer Antigens (BRCA) 1 and/or 2 and that have lost the 
homologous recombination (HR) mechanism of DNA repair regulated by BRCA-1 and 2 genes6, 7. HR is used as 
long as the BER and the nucleotide-excision repair (NER) have failed. Therefore, a concept of “synthetic lethality” 
has been suggested, in which it was established that the treatment of BRCA-deficient cancers with PARP inhib-
itors deprives BC cells of both BER and HR repair mechanisms, resulting in the arrest of the cell cycle with sub-
sequent cell death8. Since a significant proportion of TNBCs exhibits defects in HR mechanism, the BRCA-like 
character of TNBC, so called “BRCAness”, has been explored and exploited as a possible therapeutic target9.
Among PARP inhibitors, olaparib (Ola, AZD 2281, AstraZeneca, London, UK) has been assessed in chemo-
therapy regimens for BRCA-mutated or HR-deficient breast and ovarian cancer, and several clinical trials are 
ongoing10, 11. However, issues regarding its clinical potential have been raised. Indeed, whereas Ola displayed 
great anticancer activity toward high-grade serous or poorly differentiated ovarian cancer, globally controversial 
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results have been obtained with TNBC, demonstrating a certain benefit only in BRCA-mutated BCs. Recently, a 
clinical trial comparing Ola treatment in BRCA-mutated and sporadic TNBCs failed in showing positive response 
in both cases12. This result was somehow unexpected, considering that up to 24% of wild type (wt) BRCA ovarian 
cancers had previously proved to be responsive to PARP inhibitors. The controversial effect of Ola in TNBC sug-
gested that different reasons beyond BRCA status could be involved in the therapeutic outcome of Ola. First, Ola 
exhibited poor bioavailability and required a daily dosage of 800 mg/kg to achieve anticancer efficacy. Current for-
mulations of the drug only achieve sub-optimal plasma exposure of Ola, and, as a result, the amount of drug able 
to reach the tumor and to enter malignant cells is lower than expected13, 14. In addition, TNBC cells can develop 
resistance to Ola due to the overexpression of multidrug resistance proteins, such as P-glycoprotein (P-gp) and 
Breast Cancer Resistance Protein (BCRP)15. Thus, we reasoned that enhancing Ola bioavailability and tumor 
delivery could have strongly improved Ola efficacy in TNBC, even beyond BRCA status. Nanotechnology offers 
smart solutions to overcome the major challenges of bioavailability and targeted delivery of oncological drugs 
through targeted nanosystems16, 17. Among them, protein based-nanocages represent an exciting solution18. In 
particular, H-ferritin nanoparticles, consisting of a 24-mer of self-assembled human ferritin H-chain (HFn), hold 
great promise, since they combine low toxicity with high stability in biological fluids, they could be easily loaded 
with drugs and be modified by surface chemistry or genetic engineering19. HFn is specifically recognized by the 
transferrin receptor-1 (TfR1), which is over-expressed in several human cancer subtypes, including TNBC20, 
and promotes the cellular internalization of these nanoparticles. HFn nanocages were demonstrated to be able 
to mediate the direct delivery of cytotoxic doxorubicin into the nuclear compartment of cancer cells through a 
self-triggered mechanism activated by enhanced ROS production21, 22. In addition, the metronomic adminis-
tration of doxorubicin-HFn nanodrug in a 4T1 mouse model of metastatic BC demonstrated potent antitumor 
efficacy associated with inhibition of angiogenesis, reduced chemoresistance and negligible cardiotoxicity23. With 
the present study, we aimed to develop a novel HFn-based nanoformulation of Ola (HOla) able to achieve tumor 
targeting, improve cellular uptake of the drug and its nuclear release. This nanocarrier was expected to greatly 
improve Ola anticancer efficacy in both BRCA-mutated and wt TNBC cells.
Results
Suitability of H-Ferritin for Ola nuclear targeting in TNBC cells. HFn nanocages were assessed for 
their capability to interact with TNBC cells, using MDA-MB 231 (PTEN wt, p53 mutant, BRCA1 wt), MDA-MB 
468 (PTEN-null, p53 mutant and BRCA1 wt) and HCC1937 (PTEN mutant, p53-null, BRCA1 mutant) cell lines. 
TNBC cells were first analyzed for membrane expression of TfR1 (Supplementary Fig. 1a) and total amount 
of cytosolic ferritin heavy chain (Supplementary Fig. 1b). Human Umbilical Vein Endothelial Cells (HUVEC) 
with high TfR1 expression were selected as control cells to determine the overall safety of HOla in healthy cells. 
TfR1 was found over-expressed in all of the selected cell lines, with HCC1937 and MDA-MB 468 displaying a 
0.5–0.6-fold higher expression compared to MDA-MB 231, whereas the amount of endogenous ferritin heavy 
chain was similar in all the tested cell lines. The binding assays, performed by flow cytometry after incubating 
the cells with 20 or 100 µg/mL of FITC-labeled HFn, demonstrated a good and dose-dependent recognition of 
all the TNBC cell lines both at 4 °C and 37 °C (Fig. 1a and b). HFn bound to MDA-MB 468 to a lesser extent, 
despite the high TfR1 expression, but nevertheless the binding remained dose-dependent. Increased percentage 
of FITC-positive cells was observed upon binding at 37 °C, which could be probably attributable to endocytic 
mechanisms (Fig. 1b). Competition assay performed on HCC1937 cells confirmed HFn specific interaction with 
TfR1-positive cells, as displayed by the 60% reduction in cell binding when an excess of unlabeled HFn was added 
as a competitor (Fig. 1c). The occurrence of HFn-TfR1 interaction was further confirmed by confocal microscopy 
at short incubation times (15 min and 1 h)(Fig. 1d). Confocal laser scanning microscopy images of TNBC cells 
incubated with FITC-labeled HFn revealed a fast internalization of the nanoparticles in all the tested cell lines. 
Indeed, HFn were recovered attached to the cell membrane after only 15 min of incubation, while they were found 
almost completely internalized after 1–3 h. In addition, the fluorescence signal of HFn dramatically dropped at 
48 h of incubation (Supplementary Fig. 2), in accordance with results from previous studies22, 23. HFn internali-
zation route was investigated by assessing the colocalization with specific markers of endocytic compartments, 
i.e. EEA1 for early endosome, GM130 for the Golgi apparatus, CatD for lysosomes, Tf for recycling endosomes 
and LAMP-1 for late endosomes. As previously observed with other cancer cell lines, HFn accumulated in early 
endosome at 1 and 3 h. The absence of colocalization with markers of Golgi, late and recycling endosomes corrob-
orated the hypothesis that HFn neither is pushed out of the cells through recycling endosomes nor is forwarded to 
the Golgi via the late endosomes. Moreover, HFn exclusion from the lysosomes suggested that the nanocages did 
not undergo lysosomal degradation within the time window explored (Supplementary Fig. 3).
Our previous studies suggested that HFn could be an ideal nanovector to trigger drugs’ nuclear delivery, by 
following the HFn nuclear translocation upon noxious stimuli21, 22. Cell stimulation with doxorubicin activates 
the intracellular ROS production, induces the massive nuclear translocation of HFn, and promotes the subse-
quent release of the cargo inside the nucleus. Although Ola specifically inhibits PARP-1, an enzyme translocated 
into the nuclear compartment concurrently to protein translation24, there is no evidence of its capability to induce 
HFn nuclear translocation. Therefore, we assessed the effect of Ola treatment on the localization of endogenous 
ferritin. Confocal microscopy images of HCC1937, MDA-MB 231 and MDA-MB 468 cells treated with 1 µM Ola 
exhibited a time-dependent accumulation of endogenous ferritin inside the nuclei, similar to what was observed 
with doxorubicin (Fig. 2)22, 23. We concluded that HFn properties could be suitable for Ola delivery.
Development of HFn-Ola nanodrug. To set up the experimental conditions for Ola loading in HFn, two 
different procedures were explored. In a first attempt, we followed a modification of the pH-dependent disas-
sembly/reassembly method already exploited for different cargo molecules (Fig. 3a)22. In detail, HFn shell dis-
assembled into monomers at alkaline pH (around 11–12). Simultaneously, hydrophobic Ola was solubilized by 
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sonication in 0.1 M NaOH, and added to the mixture of disassembled HFn monomers. Next, the pH was mildly 
brought to neutrality to allow the complete refolding of HFn cage, which naturally encloses Ola molecules. In a 
second strategy, the HFn capability to drive the uptake of metal ions was considered25. Ola was complexed with 
Cu(II) by incubation with 10 mM CuSO4. Then, the complexed drug was added to HFn and incubated to allow 
Figure 1. HFn recognition of Triple-Negative Breast Cancer cells. (a) MDA-MB 231, MDA-MB 468, HCC1937 
(for TNBC) and HUVEC cells were incubated 2 h at 4 °C in PBS buffer and 0.3% BSA with different amounts 
of FITC-labelled HFn nanoparticles (20 and 100 µg/mL). Then, cells were processed for flow cytometry, using 
untreated cells to set the positive region and the singlet gate. Reported values are the mean ± s.e. (n = 3). 
(b) MDA-MB 231, MDA-MB 468, HCC1937 (for TNBC) and HUVEC cells seeded in a multiwell plate 
were incubated 1 h at 37 °C in complete cell culture medium with different amounts of FITC-labeled HFn 
nanoparticles (20 and 100 µg/mL). Then, cells were detached, washed and processed for flow cytometry, using 
untreated cells to set the positive region and the singlet gate. Reported values are the mean ± s.e. (n = 3). (c) 
Competition assay. HCC1937 cells were incubated 1 h at 37 °C with 100 µg/mL of FITC-labelled HFn with or 
without an excess of unlabeled HFn (i.e., 5 mg) as competitor. Cells were then detached and treated for flow 
cytometry. Untreated cells have been used to set the singlet gate and the positive region. Reported values are 
the mean ± s.e. (n = 3). (d) Colocalization of HFn and TfR1. Confocal images of MDA-MB 231, MDA-MB 
468, HCC1937 (for TNBC) and HUVEC cells incubated 15 min or 1 h at 37 °C in complete cell culture medium 
with FITC-labeled HFn nanoparticles (green; 100 µg/mL). Nuclei were stained with DAPI (blue). TfR1 was 
recognized with anti-TfR1 antibody (Abcam) and labeled with an anti-rabbit secondary antibody conjugated 
with Alexa Fluor 546 (magenta; Thermo Fischer Scientific). Scale bar: 10 µm.
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Cu(II)-Ola to be incorporated in HFn as depicted in Fig. 3b. HOla was separated by free Ola through gel filtra-
tion, and the amount of recovered HFn and Ola was determined by Bradford assay and by mass spectrometry, 
respectively. HOla nanocages obtained from both procedures were analyzed by transmission electron microscopy 
(TEM): HOla obtained by Cu(II)-mediated loading strategy showed cave sphere structures, thus demonstrat-
ing that the quaternary structure was intact and correctly folded (Fig. 3c); by contrast, low-defined structures 
Figure 2. Treatment with Ola triggers nuclear translocation of endogenous HFn. Confocal microscopy images 
of MDA-MB 231, MDA-MB 468 and HCC1937 cells incubated for 1, 3 and 48 h at 37 °C with 1 µM Ola. Cells 
not previously treated with Ola were used as negative control (untreated). Nuclei were stained with DAPI (blue). 
Endogenous ferritin was recognized with anti-ferritin antibody and labeled with an anti-rabbit secondary 
antibody conjugated with Alexa Fluor 488 (green; Thermo Fischer Scientific). Scale bar: 10 µm.
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were detected upon the pH-dependent loading procedure (Fig. 3d). Moreover, results reported in Fig. 3e pointed 
out that the high hydrophobicity of Ola strongly reduced HOla yields, probably affecting its capability to accu-
rately refold into the quaternary structure after disassembly. In contrast, the Cu(II)-based strategy afforded 7-fold 
increase in loading yields, with significantly improved HOla nanocage stability in solution. HOla obtained with 
the Cu(II)-based strategy were characterized by Dynamic Light scattering (DLS) to assess their hydrodynamic 
size and the ζ-potential after loading. No significant alterations in HFn size and charge were found after Ola 
loading. Size of void HFn and HOla were 10.7 ± 2.5 nm and 14.3 ± 4.2 nm, respectively, while ζ-potential was 
−24.8 ± 0.8 mV and −20.5 ± 1.2 mV. These results suggested that Ola was essentially incorporated inside the 
nanocage and that no, or limited, residual adsorption on protein surface remained after sample isolation.
Next, Ola release from HFn was analyzed in vitro. The release kinetics was assessed by dialyzing HOla at 37 °C 
in phosphate buffer saline (PBS), pH 7.2, and measuring Ola leakage from HFn by quantitative mass spectrometry 
in the supernatants. The amount of encapsulated Ola remained constant during the first 6 h of incubation in PBS, 
then decreased by 30% at 72 h of incubation (Fig. 3f), confirming adequate stability of the nanoformulation at 
physiological pH.
HOla exhibits enhanced antiproliferative activity in cancer cells. HOla antitumor efficacy was com-
pared to that of Ola. HUVEC and TNBC cells were separately treated for 72 h with increasing amounts of HOla in 
a drug concentration range corresponding to about 1000-fold less than the reported effective dosage of free Ola 
in the same cell lines (Supplementary Fig. 4). The percentage of viable cells was assessed by MTS assay on samples 
Figure 3. Development and characterization of HOla. (a) Schematic representation of the pH-dependent 
disassembly/reassembly method used for HFn loading with Olaparib. Olaparib is represented in red. (b) 
Schematic representation of the HFn loading strategy through Olaparib pre-complexation with Cu(II). 
Olaparib is represented in green, while Cu(II) in yellow. (c) Electron microscopy images of Olaparib-loaded 
HFn nanoparticles obtained with the pH-dependent disassembly/reassembly strategy or (d) with the Cu(II) 
pre-complexation. (e) Summary of yields of HFn encapsulation with Olaparib. (f) Drug release from HOla 
nanoparticles. The kinetic of Ola release from HFn nanocages was determined by HPLC-MS quantifying the 
amount of Ola released in the dialysis medium. The nanodrug is highly stable at 37 °C in PBS buffer. The release 
from HFn nanocage is less than 3% even after 6 h incubation.
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treated with 10, 50 and 100 nM Ola or HOla and normalized toward untreated control cells. TNBC cell prolifera-
tion was not affected by treatment with 10 and 50 nM of Ola in all samples, and only slightly decreased at 100 nM 
of Ola in MDA-MB 231 (Fig. 4). This is consistent with the micromolar IC50 values reported for Ola in MDA-MB 
231, MDA-MB 468 and HCC1937 (Supplementary Fig. 4). Treatment with 10 nM of HOla did not cause any 
significant reduction in cancer cell proliferation. However, a notable decrease in cell viability was observed upon 
treatment with 50-to-100 nM of HOla drug (Fig. 4) (HOla vs. Ola, **P < 0.005; ***P < 0.0005; ****P < 0.0001 
(Student’s t-test)). Interestingly, the substantial decrease in cell proliferation upon nanomolar concentrations of 
HOla treatment revealed remarkable differences in the antiproliferative potential of free and nanoformulated 
drug (Fig. 4). HOla exhibited a 1000-fold increase in efficiency toward tumor cell proliferation as compared to Ola 
(Fig. 4 and Supplementary Fig. 4). To exclude the toxic contribution of HFn, TNBC cells were also treated with 
equal amounts of void HFn. Results displayed in Supplementary Fig. 5 demonstrated the safe profile of void HFn 
nanocages. Of note, the proliferation of HUVEC cells was not affected by the treatment with 10, 50 and 100 nM 
HOla or Ola (Fig. 4). This piece of data indicated that the nanodrug does not affect the viability of healthy cells, 
although HFn could bind these cells.
The treatment with HOla determines cell cycle arrest in G2/M phase. In the attempt to investigate 
the bases of the higher antiproliferative activity of HOla compared to Ola, we assessed the effect of nanoformula-
tion (1, 5 and 20 nM HOla) on the cell cycle of cultured TNBC cells (Fig. 5). Statistically significant arrest in G2/M 
transition was observed in TNBC cells after 24 h treatment with 20 nM HOla (HOla vs. CTRL, P < 0.05 (Student’s 
t-test)). Cell cycle arrest in G2/M phase was assessed upon treatment with Ola after 72 h of incubation, using dif-
ferent amounts of drug for each cell line depending on their drug sensitivity26 (HCC1937 and MDA-MB 468 cells 
were treated with 1, 5 and 10 µM Ola, while MDA-MB 231 cells with 10, 50 and 100 µM, according to their IC50) 
(Supplementary Fig. 6). Notably, HOla proved to be 1000-fold more effective and much faster compared to Ola. 
This result further corroborated the hypothesis that HFn strongly enhances the intracellular drug efficacy without 
changing its mechanism of action.
HOla increases PARP-1 cleavage and DNA damage. Next, we assessed the capability of HOla to 
induce DNA damage and PARP cleavage in TNBC BRCA1 mutant cells. HCC1937 were incubated with HOla 
(1, 5 and 20 nM) or Ola (20 µM) for 72 h at 37 °C in starvation medium. Then, cells were lysed and subjected to 
gel electrophoresis and western blot to evaluate PARP-1 cleavage and γ-H2AX formation. Results in Fig. 6a and 
b display the dose-dependent increase in PARP-1 cleaved fraction (Statistical significance vs. CTRL, P < 0.01 
(Student’s t-test)), which is strictly related to the Ola-mediated inhibitory effect on PARP-1. According to the 
results obtained by the proliferation experiments, HOla exhibited a 1000-fold increase in efficacy compared to 
Ola: cleaved vs. total PARP-1 ratio at 5–20 nM HOla was comparable to that obtained with 20 µM Ola. The proteo-
lytic cleavage of PARP-1 was combined with the induction of apoptosis, as demonstrated by Annexin V exposure 
(Fig. 6c) (Statistical significance vs. CTRL, ***P < 0.0005; vs. Ola §P < 0.05, §§P < 0.005 and §§§P < 0.0005).
The capability of HOla to induce DNA damage was confirmed by formation of nuclear γ-H2AX. Western blot 
analysis and confocal microscopy imaging of HCC1937 cells treated for 72 h with increasing concentration of 
HOla (1, 5 and 20 nM) and Ola (20 µM) revealed the efficacy of nanocaged Ola in inducing the phosphorylation 
of histone H2AX (γH2AX) (Fig. 7) (Statistical significance vs. CTRL, P < 0.0001 (Student’s t-test)).
Figure 4. Viability of TNBC cells treated with Ola or HOla nanoparticles. HCC1937, MDA-MB 231, MDA-MB 
468 and HUVEC cells were treated with 10, 50 and 100 nM Ola or HOla for 72 h. Viability was assessed 
by measuring the conversion of MTS into formazan. Reported values are the mean of six replicates ± s.e., 
normalized on cell proliferation of untreated cells, respectively. Statistical significance of HOla vs. free drug, 
**P < 0.005; ***P < 0.0005; ****P < 0.0001 (Student’s t-test).
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Figure 5. Treatment with HOla causes a cell cycle arrest in G2/M phase. HCC1937, MDA-MB 231 and 
MDA-MB 468 cells were incubated at 37 °C for 24 h with 1, 5 and 20 nM of HOla. Then cells were processed 
for flow cytometry and stained with Propidium Iodide. Untreated cells have been used as controls. Graphs 
represented the mean percentage of events in G1, S and G2/M phase, respectively ± s.e. (n = 3). Statistical 
significance of HOla vs. CTRL, *P < 0.05; **P < 0.01 (Student’s t-test).
www.nature.com/scientificreports/
8SCIenTIFIC REPORTS | 7: 7505  | DOI:10.1038/s41598-017-07617-7
HFn mediates nuclear delivery of Ola. To explain the increased efficacy of Ola upon HFn nanoformu-
lation, we hypothesized a positive contribution of HFn in drug delivery. Indeed, previous studies have demon-
strated that HFn could function as a “Trojan horse”, by transporting cytotoxic drugs directly inside the nuclear 
compartment through a self-triggered mechanism of translocation, thus improving drugs’ activity and circum-
venting the mechanisms of multidrug resistance held by TNBC cells21, 22. Therefore, to investigate whether HFn 
could play an active role in the nuclear delivery of Ola, we treated the cells with 1 or 5 nM Ola or HOla and 
measured the amount of drug inside the nuclear compartment after 24 h. Results reported in Fig. 8 show that 
HFn did not affect Ola delivery in the cytosol, while it played a crucial role in improving its nuclear accumulation 
(Statistical significance HOla vs. Ola, P < 0.05 (Student’s t-test)), thus providing a rationale for the exponential 
increase in antitumor efficacy of HOla compared to Ola.
Figure 6. HOla is efficient in mediating PARP-1 cleavage due to Olaparib inhibition in TNBC cells. (a) 
HCC1937 were treated with increasing concentration of nanoformulated Ola (HOla; 1, 5 and 20 nM) in the 
presence of 5% FBS supplemented RPMI1640 medium for 72 h. As positive control, cells treated with 20 µM 
Ola were used. At the end of incubation, cells were lysed and subjected to western blot analysis. (b) Relative 
amounts of cleaved PARP-1 were quantified by densitometry using ImageJ Software. Reported values are the 
mean of 6 samples ± s.e. Statistical significance vs. CTRL, **P < 0.01 (Student’s t-test). (c) Cell death assay of 
HCC1937 cells treated with increasing concentration of nanoformulated Ola (HOla; 1, 5 and 20 nM) in the 
presence of 5% FBS supplemented RPMI1640 medium for 72 h. As positive control, cells treated with 20 µM 
Ola were used, while untreated cells were used as negative control (untreated). Reported values represent the 
mean ± s. e. of three replicates. (Statistical significance vs. CTRL, ***P < 0.0005; vs. Ola §P < 0.05, §§P < 0.005 
and §§§P < 0.0005).
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Discussion
Olaparib has been recently approved in clinical practice for treatment of BC with germline mutations, including 
BRCA-mutated TNBC. Some phase I and II clinical trials have demonstrated inhibition of PARP as a smart strat-
egy to chemosensitize malignant cells. By preventing DNA recovery by BER, PARP inhibitors lead to enhanced 
susceptibility to cytotoxic chemotherapy or, in the best cases, PARP inhibition itself could induce cell death in 
those cancers defective for HR mechanism10–12, 27, 28. Clinical data were initially encouraging for BRCA-mutated 
cancers10. A similar success was expected also for sporadic BRCA-wt TNBC treated with Ola, since various 
Figure 7. HFn increases Ola propensity to induce DNA damage in TNBC cells. (a) HCC1937 were treated 
with increasing concentration of nanoformulated Ola (HOla; 1, 5 and 20 nM) in the presence of 5% FBS 
supplemented RPMI1640 medium for 72 h. As a positive control, cells treated with 20 µM Ola were used. At the 
end of incubation, cells were lysed and subjected to western blot analysis. (b) The percentage of phosphorylated 
histone H2AX (γH2AX) were quantified by densitometry using ImageJ Software. Reported values are the mean 
of 6 samples ± s.e. Statistical significance vs. CTRL, ****P < 0.0001 (Student’s t-test). (c) Confocal microscopy 
images of HCC1937 cells treated with increasing concentration of nanoformulated Ola (HOla; 1, 5 and 20 nM) 
in the presence of 5% FBS supplemented RPMI1640 medium for 72 h. As positive control, cells treated with 
20 µM Ola were used, while untreated cells were used as negative control (untreated). Nuclei were stained 
with DAPI (blue). DNA damage was recognized with anti-γH2AX antibody and labeled with an anti-rabbit 
secondary antibody conjugated with Alexa Fluor 488 (green; Thermo Fischer Scientific). Scale bar: 10 µm.
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basal-like breast cancers are characterized by defects in DNA repair pathways. Hence, researchers have started 
to exploit the intrinsic “BRCAness” of TNBC29. Unfortunately, a relevant phase II clinical trial was conducted on 
both BRCA-mutated and sporadic TNBC patients treated with Ola, but results were discouraging, mainly in case 
of wt BRCA TNBCs, with no significant clinical response in sporadic breast cancers12.
Here, a novel nanodrug consisting of H-Ferritin nanoparticle loaded with Ola (HOla) was developed, tested 
and compared to free Ola for in vitro efficacy on three different TNBC cell lines. The rationale of our study was an 
optimization of the sub-cellular delivery of Ola, obtained by encapsulation of the drug into nuclear-targeted HFn 
nanocarrier. By pushing the drug into cancer nuclei, HOla was expected to enhance the anticancer potential in 
both BRCA-mutated and sporadic TNBC, by exploiting TNBC BRCAness.
HOla showed a remarkable anticancer activity as compared to Ola in all TNBC lines, with maximal differ-
ences at 100 nM (Fig. 4). While wt BRCA-TNBC cells (MDA MB-468 and MDA-MB-231) were poorly sensitive 
to free Ola, exhibiting global sustained viability even upon treatment with 100 nM, they surprisingly responded 
to equal doses of HOla, showing a marked decrease in viability down to 40%. In BRCA-mutated HCC1937 cells, 
Ola showed irregular anticancer activity in accordance with the reported clinical scenario. By contrast, HOla 
demonstrated increased dose-dependent cytotoxicity also in this TNBC subset. The negligible toxicity of void 
HFn nanocages (Supplementary Fig. 5), together with the conserved viability recovered in HUVEC cells treated 
with HOla (Fig. 4), reasonably excluded a contribution of the nanocarrier in the cytotoxic effect. These findings 
suggest that monotherapy based on HOla could provide potent anticancer efficacy both in BRCA-mutated and 
wt BRCA TNBC. A possible explanation for HOla efficacy in wt BRCA TNBC cells could reside in the genomic 
instability and increased cytogenetic aberrations that are associated to PARP inhibition even in HR-proficient 
cells30. Considering that many TNBCs exhibit various genomic alterations and features of “BRCAness”, it is not 
surprising that strong cytotoxicity of Ola can be achieved at certain dosages even in absence of BRCA mutations. 
Conversely, the anticancer efficacy of Ola in BRCA-mutated TNBC was expected based on the clinical literature, 
due to the enhanced synthetic lethality exploited by anti-PARP treatment. However, also under this setting, a sig-
nificant improvement was observed with HOla, thus confirming the strong relevance of a proper nuclear delivery 
as a key for successful anti-PARP therapy. These data suggest that HFn-mediated nanodelivery of Ola could have 
a major impact also in the treatment of BRCA-mutated TNBCs.
The encapsulation of Ola in HFn nanocages offers a unique evolution in the drug aptitude to address human 
cancer cells and be internalized therein. HFn is actively cross-recognized by TfR1, a receptor involved in the regu-
lation of intracellular iron. Under physiological conditions, TfR1 is ubiquitously expressed at low levels and binds 
transferrin26, 31. Interestingly, TfR1 gene is upregulated in most primary and metastatic cancer cells because higher 
amount of iron is required to support cancer cell proliferation. Therefore, TfR1 has been suggested as a potential 
target for malignant cells31. In addition, TfR1 expression has been proposed as a prognostic predictor, since it is 
related both to tumor stage and cancer progression32. As confirmed by flow cytometry, TNBC cell lines used in this 
study showed marked overexpression of TfR1 (Supplementary Fig. 1), and, as a consequence, a huge extent of HFn 
binding (Fig. 1). The HFn recognition of TfR1 triggered HFn internalization in TNBC cells, with prompt transfer 
from the membrane to the cytosolic interspace, and than to the nucleus when triggered by DNA damaging events33.
We have previously established that HFn is able to translocate into the nucleus and to promote the nuclear 
accumulation of DNA-damaging loaded drugs22. The same phenomenon is likely reproduced by HOla. Ola 
administration induced a DNA-damaging event that triggered the recruitment of ferritin inside the nuclear com-
partment (Fig. 2). Following this mechanism, HOla was massively delivered into the nuclear space where it pro-
moted a targeted release of Ola on PARP system, enhancing the impairment of DNA repair and leading to cell 
death. After 72 h of incubation with HOla, the residual proportion of cytosolic drug was negligible, as almost the 
entire amount of drug was transferred into the nuclear compartment (Fig. 8). A maximum of 3 ng/mL Ola per 
mg/mL protein could be internalized into the nucleus even at increasing HOla concentrations, probably due to 
achieved saturation of the nuclear delivery system. Notably, 1 nM HOla was sufficient to reach this maximum 
threshold of Ola concentration in the nucleus.
Figure 8. HOla promotes the drug transport into the nuclear compartment. HCC1937 were treated with 
increasing concentration of Ola or HOla (1 and 5 nM) for 72 h. At the end of incubation, cells were collected by 
tripsinization and subjected to cell fractionation to obtain crude nuclei and cytoplasmic extract. The protein 
content of each fraction was assessed by Bradford assay and used for normalization. Samples were processed for 
HPLC-MS quantification of Ola. Reported values are the mean of 2 samples ± s.e. Statistical significance HOla 
vs. Ola *P < 0.05 (Student’s t-test).
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All the TNBC cell lines used in this study globally showed a significant increase in anticancer efficacy by HOla. 
Theoretically, altered response to HOla could be observed in other TNBC cell lines, since HFn nuclear transloca-
tion could be differently effective. Moreover, different TfR1 expression levels could reduce or vary the efficacy of 
HOla. Further studies are needed to exactly disclose the incidence of these two parameters; however, our results 
support the therapeutic success of HOla in a relevant panel of TNBCs. Confocal microscopy demonstrated a 
prompt nuclear translocation of HFn in all TNBC cell lines (Fig. 2), suggesting that the nuclear delivery could 
be similarly effective in both BRCA-mutated and sporadic TNBCs. Moreover, HOla showed a greater anticancer 
efficacy, as compared to free Ola, also in MDA-MB 468 cells, which displayed high over-expression of TfR1 but 
low binding with HFn. Further confirmation of the higher efficacy of HOla was obtained investigating the PARP 
inhibition: the cleaved/full length PARP ratio was higher with HOla than with Ola (Fig. 6). The HOla-mediated 
inhibition of DNA repair was at least three orders higher than that induced by Ola, as demonstrated by the per-
centage of phosphorylated histone H2AX, here chosen as a marker of DNA damage (Fig. 7)34. As a consequence, 
cytotoxicity of HOla was mainly elicited in the G2/M phase, where a checkpoint is committed to arrest the cell 
cycle when DNA damage is not repaired (Fig. 5)35. Notably, the increased cleavage of PARP-1 was dependent on 
Ola concentration, and HOla improved drug efficacy in comparison to Ola alone. Western blot data reported that 
this effect was also associated to an increase in the amount of total PARP-1. A physiological cellular response to 
Ola is known to take place in HCC1937 cells: Ola-mediated PARP-1 cleavage is sensed by cells and stimulates the 
increased expression of PARP-1 in the attempt to maintain correct levels of full length PARP-136. HOla is not able 
to circumvent this issue, since the over-expression of PARP-1 in response to the increase of PARP-1 cleavage is a 
physiological mechanism.
Another crucial advantage supporting the potential of HOla for TNBC treatment resides in its safety towards 
healthy cells. Excellent viability was observed in HUVEC cells treated with HOla despite high expression of TfR1, 
consistent with Ola ineffectiveness toward healthy cells (Fig. 4).
In conclusion, this is the first report demonstrating the effectiveness of nanoformulated Ola used as a cytotoxic 
monotherapy against TNBC. Recently, Ola has been loaded into PLGA nanoparticles, tested on lung and breast 
cancer cells as a chemosensitizer and compared to wortmanin, another chemosensitizer based on PI3-kinase 
inhibition37. However, while nanoformulated wortmanin showed a greater efficacy as a chemosensitizer com-
pared to the drug alone, nanoformulated Ola demonstrated much less consistent results, particularly if conju-
gated to etoposide or docetaxel37. Ola is attracting growing interest for TNBC clinical treatment, although results 
from clinical trials have been controversial so far. The conventional indication for Ola is chemosensitization 
of BRCA-mutated TNBC to cytotoxic chemotherapy such as cisplatin, while Ola is generally not administered 
as a monotherapy nor used for BRCA wt cancers27, 28. However, achieving PARP inhibition also in BRCA wt 
TNBC cells with features of “BRCAness” is attracting attention among clinicians. A few trials aiming at exploring 
the TNBC response to Ola in relation to the genetic profile and the protein expression of the tumor are ongo-
ing, and hopefully will identify useful predictors of clinical response to the drug38, 39. Our findings suggest that 
HFn-mediated nuclear delivery of Ola into TNBC cells could strongly enhance PARP-inhibition activity. It is 
plausible that HOla itself could provide enough cytotoxic activity without the need of additional drugs on both 
BRCA-mutated and non-mutated TNBCs. These findings are even more relevant considering the low IC50 of 
HOla and the biocompatibility profile of H-Ferritin. Further studies will be required to confirm the efficacy of 
HOla in vivo as a promising therapeutic option for TNBC.
Methods
HFn production. HFn nanocages were produced in E. coli by DNA recombinant technology and purified 
as previously described22. HFn was labelled with fluoresceine isothiocyanate (FITC) for interaction studies with 
TNBC cell lines.
HFn loading with Olaparib. HOla was prepared using two different procedures: i) the disassembly/reas-
sembly method22 and ii) the drug complexation with Cu(II)24. i) HFn nanoparticles (2 mg) were disassembled 
in 1.5 mL of 0.15 M NaCl by raising the pH to 12. Then, Olaparib powder (0.5 mg; Alsachim, C3734) previously 
solubilized by 1 h of sonication (Bransonic 12, Branson) in NaOH 0.1 M (0.5 mL) was added to the solution of 
disassembled HFn and incubated for 10 minutes at room temperature (RT). Then, the pH value was lowered to 
7.5 using 0.1 M HCl. The resulting solution was stirred at RT for 2 h in order to favor the nanoparticle refolding. 
The solution was concentrated through a 100 kDa Amicon filter (Millipore) and loaded to Zeba™ Spin Desalting 
Column (Thermo Fischer Scientific) to remove free Ola. ii) Olaparib powder, solubilized as previously described, 
was incubated for 10 min at RT with 10 mM CuSO4 obtaining a Cu(II)-Ola complex. The complexed drug was 
added to HFn (2 mg) and incubated 2 h at RT. HOla was separated from free Ola by a gel filtration to Sephadex 
G-25 column. The amount of HFn in HOla sample was determined assessing the protein content by Bradford 
assay, while the amount of encapsulated Ola was determined by quantitative MS analysis, as described below.
Ola quantification. The quantification of Ola was performed by liquid chromatography tandem mass 
spectrometry (LC–MS/MS) method. For quantification of Ola encapsulated in HFn nanocages, 100 µL of cold 
acetonitrile were added to 50 µL of HOla solution to disassemble the nanoparticles; then, samples were centri-
fuged 10 min at 14000 rpm to precipitate HFn. Obtained samples were spiked with Ola-d8 as internal standard 
(Alsachim, Cat: C3684, IS), diluted with water/acetonitrile 95/5 and directly injected for the analysis. To study 
in vitro release of Ola, samples were treated as follow: 500 µL of samples were spiked with IS, and a liquid-liquid 
extraction was performed with ethyl acetate. Nuclear and cytoplasm extracts were used to quantify Ola subcel-
lular accumulation, 100 µL of samples were spiked with IS, 200 µL of cold acetonitrile was added and the super-
natant was separated by 10 min centrifugation (14000 rpm) and evaporated under vacuum. Obtained samples 
were dissolved in 50 µL of water/acetonitrile 50/50 and analysed. All samples were extracted and analyzed in 
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triplicate. The liquid chromatography system was composed by a Dionex Ultimate 3000 Rapid Separation LC sys-
tem (DionexThermo Fischer, Rodano Milanese, Italy). Mass analyses were performed on a ABSciex 4000 Q-trap 
LC-MS/MS system (AB Sciex, FosterCity, CA, USA). Ionization of analytes was performed using electrospray 
ion source (ESI) in positive mode. Separation of the analytes was carried out on a Phenomenex Gemini C18 col-
umn (150 mm × 2 mm i.d. 3). Calculation of Ola concentrations in biological samples was performed on three 
different calibration curves prepared in the same conditions of the samples described before: 0, 2–10 ng/mL for 
liquid-liquid extraction, 0, 5–10 ng/mL for the nuclear and cytoplasm extracts and 25–750 ng/mL for loading 
samples.
HOla characterization by Dynamic Light Scattering and ζ-potential. The HFn hydrodynamic 
diameter and ζ-potential were analyzed on a Zetasizer Nano ZS ZEN3600 (Malvern Instruments Ltd) operating 
at light source wavelength of 633 nm and a fixed angle of 173°. For Dynamic Light Scattering (DLS) analysis, the 
purified samples were diluted in PBS buffer, pH 7.2. For ζ-potential, the samples were diluted in milli-Q water 
(Millipore). The results were expressed as mean ± standard deviation of three measurements.
Transmission Electron Microscopy. A drop of HFn suspension was placed on the Formvar net and dried 
at RT. Then, the net was washed twice with milli-Q water, stained with uranil-acetate 1% for 30 min at RT and 
dried over night at RT. Samples were examined by Transmission Electron Microscopy (Tecnai Siprit, FEI).
Kinetics of Ola spontaneous release in vitro. HOla was stored in a dialysis device and kept in a PBS bath 
at 37 °C for three days. At predetermined time points (15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 24 h, 48 h, 72 h), the 
amount of released drug was quantified by HPLC coupled mass spectrometry and the buffer was replaced after 
each measurement in order to maintain sink condition.
Cell cultures. MDA-MB 468 cells were cultured in Dulbecco’s Modified Eagle’s Medium High Glucose 
(DMEM), supplemented with 10% fetal bovine serum (FBS), L-glutamine (2 mM), penicillin (50 UI/mL) and 
streptomycin (50 mg/mL). HCC1937 cells were cultured in RPMI 1640 medium, supplemented with 10% FBS, 
L-glutamine (2 mM), penicillin (50 UI/mL) and streptomycin (50 mg/mL). MDA-MB 231 cells were cultured 
in MEM Medium, supplemented with 10% FBS, L-glutamine (2 mM), penicillin (50 UI/mL) and streptomycin 
(50 mg/mL), while HUVEC were cultured in EGM™-2 Bullet kit medium (Lonza). All cell lines grew at 37 °C and 
5% CO2 in a humidified atmosphere and were subcultured prior to confluence using trypsin/EDTA. Cell culture 
medium and chemicals for cell culture were purchased from Euroclone.
TfR1 expression. MDA-MB 231, MDA-MB 468, HCC1937 and HUVEC cells (5 × 105) were immunodeco-
rated in FACS tubes with anti-TfR1 antibody (1 µg/tube; clone ICO-92; Thermo Fischer Scientific) in Phosphate 
buffer (PBS), 2% Bovine Serum Albumin (BSA; Sigma) and 2% goat serum (Euroclone) for 30 min at RT. Then, 
cells were washed thrice with PBS and immunodecorated with Alexa Fluor 488 goat anti-mouse secondary 
antibody (1 µL/tube; Thermo Fischer Scientific) in PBS, 2% BSA and 2% goat serum for 30 min at RT. After 
three washes with PBS cells were analyzed by CytoFLEX flow cytometer (Beckman Coulter). 20,000 events were 
acquired for each analysis, after gating on viable cells and on singlets. A sample of cells immunodecorated with 
the secondary antibody only was used to set the region of positivity.
Ferritin heavy chain expression. About 5 × 105 cells were lysed with 200 µL lysis buffer (20 mM Tris HCl 
pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% glycerol, 1 mM Na3VO4, 10 mM NaF, Protease Inhibitor 
Cocktail, 1 mM PMSF). Protein content in lysate was quantified using the Coomassie Plus Protein Assay Reagent 
(Thermo Fisher Scientific) with Bovine Serum Albumin (BSA) as standard protein. Approximately 30 µg of pro-
tein from each sample were separated by SDS-PAGE and then transferred onto PVDF membrane. The mem-
brane was blocked in 5% BSA in TBS with 0.1% Tween 20 for 1 h. The membrane was incubated 2 h at RT with 
rabbit-monoclonal antibody against Ferritin heavy chain (Abcam, Ab7332) at 1:1000 dilution and with mouse 
monoclonal antibody anti-α-tubulin (Sigma) at 1:1000 dilution in 5% BSA in TBS with 0.1% Tween 20. The 
membranes were washed three times with TBS with 0.1% Tween 20 and reacted 1 h with the secondary antibody 
anti-rabbit conjugated with horseradish peroxidase (1:5000; Abcam) The bound antibody was revealed using ECL 
star reagent (Euroclone) and the chemoluminescence signal was detected using the Chemidoc System (Biorad). 
Quantification has been performed with imageJ software on three samples/group and results have been expressed 
as mean ± s.e.
In tube-cell binding assay at 4 °C. 5 × 105 cells/tube were collected and incubated for 2 h at 4 °C in 
blocking buffer (PBS, 0.3% BSA) supplemented with 20 and 100 µg/mL of FITC-labelled HFn. After incubation, 
cells were washed three times with PBS, suspended in 0.5 mL of PBS and analyzed by CytoFLEX flow cytometer 
(Beckman Coulter). 20,000 events were acquired for each analysis, after gating on viable cells and on singlets. A 
sample of untreated cells was used to set the appropriate gates.
In plate-cell binding assay at 37 °C. MDA-MB 231, MDA-MB 468 and HCC1937 cells were seeded at a 
concentration of 2.5 × 105 cells/well. The day after, cells were incubated 1 h at 37 °C in culture medium supple-
mented with 20 and 100 µg/mL of FITC-labelled HFn. After incubation, cells were washed three times with PBS, 
detached from the plate with trypsin/EDTA, suspended in 0.5 mL of PBS and analyzed by CytoFLEX flow cytom-
eter (Beckman Coulter). 20,000 events were acquired for each analysis, after gating on viable cells and on singlets. 
A sample of untreated cells was used to set the appropriate gates.
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Competition assay. HCC1937 cells were seeded at a concentration of 5 × 105 cells/well. The day after, 
100 µg/mL of FITC-labelled HFn were incubated with the cells for 1 h at 37 °C with or without 5 mg of unlabelled 
HFn added as competitor. After incubation, cells were washed three times with PBS, detached from the plate 
with trypsin/EDTA, suspended in 0.5 mL of PBS and analyzed by CytoFLEX flow cytometer (Beckman Coulter). 
10,000 events were acquired for each analysis, after gating on viable cells and on singlets. A sample of untreated 
cells was used to set the appropriate gates.
Confocal laser scanning microscopy. Cells were cultured until sub-confluence on cover glass slides 
pre-coated with collagen, and incubated with FITC-labelled HFn for different time periods. To evaluate internal-
ization, TfR1 colocalization and sub-cellular localization, 100 µg/mL of FITC-labelled HFn were incubated with 
cells for 15 min, 1, 3, 24 and 48 h at 37 °C. To evaluate Ola capability to trigger nuclear translocation of endoge-
nous ferritin cells were incubated in presence of Ola 1 µM for 1, 3, and 48 h at 37 °C. After incubations, cells were 
washed with PBS, fixed for 5 min with 4% paraformaldehyde (Sigma) and then treated for 5 min with 0.1% Triton 
X-100 (Sigma). A blocking step was performed for 1 h at RT with a solution containing 2% BSA (Sigma), 2% goat 
serum (Euroclone) and 0.2 µg/mL DAPI (4’,6-diamino-2-phenylindole; Thermo Fischer Scientific) in PBS. Golgi 
apparatus, lysosomes, early and recycling endosomes were stained for 2 h at RT with Golgi marker 130 (GM-
130; at a 1:100 dilution; clone 35; BD Biosciences), Cathepsin D (CatD; 1:50; clone BC011; Calbiochem), Early 
Endosomes Antigen-1 (EEA-1; 1:1000; clone 14; BD Biosciences) and Transferrin (Tf; 1:100; clone 5G2; Abcam) 
antibodies, respectively, and revealed by Alexa Fluor 546-conjugated antibody against murine IgGs (Thermo 
Fischer Scientific) at a 1:300 dilution by incubating for 2 h at RT in PBS, 2% BSA, 2% goat serum. Endogenous 
ferritin was stained with the anti-ferritin heavy chain antibody (1:2000; ab65080; Abcam) and revealed by Alexa 
Fluor 488-conjugated antibody against rabbit IgGs (Thermo Fischer Scientific) at a 1:300 dilution by incubating 
for 2 h at RT in PBS, 2% BSA, 2% goat serum. DNA damage was revealed by the anti-γH2AX antibody (1:1000; 
ab11174; Abcam) and Alexa Fluor 488-conjugated antibody against rabbit IgGs (Thermo Fischer Scientific) at a 
1:300 dilution by incubating for 2 h at RT in PBS, 2% BSA, 2% goat serum. TfR1 colocalization was revealed with 
the anti-TfR1 antibody (1:200; ab84036; Abcam) and recognized by Alexa Fluor 546-conjugated antibody against 
rabbit IgGs (Thermo Fischer Scientific) at a 1:300 dilution by incubating for 2 h at RT in PBS, 2% BSA, 2% goat 
serum. Images were acquired with Leica SPE microscope confocal system equipped with laser excitation lines 
405 nm, 488 nm, 514 nm and 633 nm or with Leica SP8 microscope confocal system equipped with laser excita-
tion lines 405 nm, 488 nm, 535 nm and 633 nm. Images were acquired with 63× magnification oil immersion 
lenses at 1024 × 1024 or 512 × 512 pixel resolution.
Cell viability assay. MDA-MB 231, MDA-MB 468 and HCC1937 cells were seeded on a 96 multi-well dish 
at the density of 5000 cells cm−1. Then, cells were incubated with different amounts of Ola (Ola: 10, 50, 100 nM 
and 10, 20, 50, 100 and 200 µM; HOla: 10, 50, 100 nM). Untreated cells were used as controls. After 72 h of treat-
ment, cells were washed with PBS and incubated for 3 h at 37 °C with 0.1 mL of a stock solution of 3-(4,5-dim
ethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and phenazine 
ethosulfate (PES) previously diluted 1:10 in DMEM medium without phenol red (CellTiter 96® AQueous One 
Solution Reagent; Promega). Absorbance was read in a microplate reader (BioTek) using a testing wavelength of 
490 nm and a reference wavelength of 620 nm. The results were normalized on viability of untreated samples and 
expressed as means ± s.e.
Cell Cycle analysis. 2.5 × 105 cells were seeded on a 12 multi-well dish the day before. Then, cells were incu-
bated with different amounts of HOla (1, 5, 20 nM) for 24 h in medium supplemented with FBS 5%. Untreated 
cells were used as negative control, while cells treated for 72 h with free Ola were used as positive controls 
(MDA-MB 468 and HCC1937 cells: 1, 5 and 10 µM; MDA-MB 231: 10, 50 and 100 µM). At the end of the incu-
bation time, cells were washed twice with PBS, detached with Trypsin/EDTA solution and transferred in FACS 
tubes. Then, cells were fixed with cold ethanol 95% for 1 h, labelled with staining solution (PBS supplemented 
with 80 µg/mL Iodide Propidium (Sigma), 100 µg/mL RNAseA (Sigma) and 0.1% Triton X-100 (Sigma)) and 
acquired with CytoFLEX flow cytometer (Beckman Coulter).
Evaluation of PARP-1 cleavage and histone H2AX phosphorylation. HCC1937 cells cultured in a 
6-wells plate were treated for 72 h with increasing concentration of HOla (1, 5 and 20 nM) in RPMI 1640 medium 
supplemented with 5% FBS. Cells treated with 20 µM of free Ola were used as positive control. Negative control 
was represented by untreated cells. Cells were lysed with 200 µL lysis buffer (20 mM Tris HCl pH 7.6, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 1% glycerol, 1 mM Na3VO4, 10 mM NaF, Protease Inhibitor Cocktail, 
1 mM PMSF), and the protein content was quantified using the Coomassie Plus Protein Assay Reagent (Thermo 
Fisher Scientific) with BSA as standard protein. Approximately 30 µg of protein from each sample were sep-
arated by SDS-PAGE and transferred onto PVDF membrane. The membrane was blocked in 5% BSA in TBS 
with 0.1% Tween 20 for 1 h. For evaluation of PARP-1 cleavage, the membrane was incubated overnight with 
rabbit-monoclonal antibody against PARP-1 (clone 46D11; Cell Signalling) at 1:1000 dilution and with mouse 
monoclonal antibody anti-α-tubulin (Sigma) at 1:1000 dilution in 5% BSA in TBS with 0.1% Tween 20 for 1 h. To 
assess histone H2AX phosphorylation, the membrane was incubated overnight with rabbit-monoclonal antibody 
against histone H2AX (#2595; Cell Signalling) at 1:1000 dilution, phosphorylated histone H2AX (Ser139) (clone 
20E3; Cell Signalling) at 1:1000 dilution, or a mouse monoclonal antibody anti-α-tubulin (Sigma) at 1:1000 dilu-
tion in 5% BSA in TBS with 0.1% Tween 20 for 1 h. The membranes were washed three times with TBS with 
0.1% Tween 20 and reacted 1 h with the secondary antibody anti-rabbit conjugated with horseradish peroxidase 
(1:5000; Abcam) or with the secondary antibody anti-mouse conjugated with horseradish peroxidase (1:5000; 
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Abcam), respectively. The bound antibody was revealed using ECL star reagent (Euroclone) and the chemolumi-
nescence signal was detected using the Chemidoc System (Biorad).
Cell death assay. HCC1937 cells seeded on a 6-well plate at 2 × 105 cells/well were treated for 72 h with 
increasing concentration of HOla (1, 5 and 20 nM) in RPMI 1640 medium supplemented with 5% FBS. As pos-
itive control, cells treated with 20 µM of free Ola were used. Negative control was represented by untreated cells. 
Then, cells were collected, washed thrice with PBS and treated for FACS analysis according to Annexin V-PE-Cy5 
Apoptosis Detection Kit manufacturer’s protocol (BioVision). Briefly, cells were suspended in Binding Buffer and 
incubated 5 min with 5 µL of Annexin V-PE-Cy5. Cells were analyzed within 1 h on CytoFLEX flow cytometer 
(Beckman Coulter). 20,000 events were acquired for each analysis.
Quantification of Nuclear accumulation of Ola. HCC1937 cells were seeded in a 6-multiwell plate at 
1 × 106 cells/well. Cells were incubated at 37 °C with Ola or HOla (5 and 1 nM) for 24 h. At the end of incuba-
tion, cells were harvested with Trypsin/EDTA and centrifuged 5 min at 2,000 rpm. Pellets were washed twice 
with PBS, suspended in 1 mL of Nuclei Extraction Buffer (10 mM Hepes, pH 7.4, 320 mM Sucrose, 5 mM 
MgCl, 1% Triton X-100) and incubated on ice for 10 min. Then, nuclei were pelleted by 5 min centrifugation at 
2,000 rpm and washed twice with 1 mL of Nuclei Wash Buffer (10 mM Hepes, pH 7.4, 320 mM Sucrose, 5 mM 
MgCl). Purified nuclei were processed for HPLC/MS evaluation of Ola content, as reported above. Protein con-
tent of purified nuclei was assessed by Bradford assay and used for normalizations. The purity of nuclei and 
cytoplasmatic fractions was checked by western blot using anti-rabbit-α-tubulin (1:1000 dilution, Sigma) and 
anti-rabbit-monoclonal antibody against histone H2AX (1:1000 dilution, #2595; Cell Signalling), and reported 
in Supplementary Fig. 7.
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